Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $82

Author: Benzinga Newsdesk | August 07, 2025 08:04am
Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price target from $77 to $82.

Posted In: MIRM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist